-
Baidu Health and Chongqing’s Fifth People’s Hospital Collaborate on Integrated Medical Services
•
Baidu Health has entered into a partnership with the Fifth People’s Hospital of Chongqing, a Class 3A general hospital in China. The collaboration aims to combine the hospital’s disciplinary and location advantages with Baidu Health’s strengths in online diagnosis, treatment, digitalization, and artificial intelligence (AI) to establish an integrated online-offline…
-
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
•
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based in China, has entered into a licensing agreement with Qilu Pharmaceutical, granting the company clinical development, manufacturing, and commercialization rights to its PCSK9 siRNA drug RBD7022 in Greater China, which includes mainland China, Hong Kong,…
-
CStone Pharmaceuticals Regains Exclusive Rights to Tibsovo in Greater China and Singapore
•
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced an agreement with French pharmaceutical company Servier that returns exclusive development, manufacturing, and commercialization rights to Tibsovo (ivosidenib) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan, as well as Singapore. Originally developed by US-based Agios Pharmaceuticals,…
-
Yifan Pharmaceutical’s F-652 Shows Promise in Phase II Clinical Trial for ACLF
•
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has reported positive outcomes from a Phase II clinical trial for F-652, a product developed by its subsidiary Evive Biotech Ltd, in the treatment of acute-on-chronic liver failure (ACLF). The trial demonstrated that F-652 not only exhibits good safety and…
-
Takeda Ends Gene Therapy Collaboration with JCR Pharmaceuticals, Returns IP
•
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced the termination of a 2022 collaboration agreement with fellow Japanese firm JCR Pharmaceuticals Co., Ltd. (TYO: 4552) for the development of gene therapies. As a result of the termination, Takeda will return all research outcomes and patents to JCR. This strategic decision…
-
Sanofi Halts Development of Tusamitamab Ravtansine After Missed Trial Endpoints
•
Sanofi (NASDAQ: SNY) has announced the discontinuation of its antibody-drug conjugate (ADC) tusamitamab ravtansine following disappointing results from a Phase III trial in metastatic non-squamous (NSq) non-small cell lung cancer (NSCLC) patients with high CEACAM5 expression. The trial did not meet its dual primary endpoints, as indicated by an interim…
-
CNIPA Releases Updated Patent Law Rules with Pharma Industry in Focus
•
The China National Intellectual Property Administration (CNIPA) has announced the “Decisions of the State Council on Amending the Patent Law Implementation Rules,” set to take effect from January 20, 2024. These amendments are particularly significant for the pharmaceutical sector, as they provide detailed regulations on patent compensation terms that were…
-
China’s CDE Issues Draft Guidelines for Overseas Drug Market Approval Filings
•
China’s Center for Drug Evaluation (CDE) has unveiled a draft set of “Application Material Requirements” aimed at streamlining the market approval process for drugs that are either listed overseas and subsequently transferred to domestic production or are therapeutic biologic products. The draft, which is open for public consultation for a…
